Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men
and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine
whether sildenafil may be an effective treatment for SSc-MEP.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Louisiana State University Health Sciences Center in New Orleans